Edition:
United States

GSK and Innoviva announce positive data from COPD study


Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Glaxosmithkline Plc :GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE.GSK - ‍POSITIVE DATA FROM A STUDY COMPARING A ONCE-DAILY LAMA AND LABA FIXED-DOSE COMBINATION, ANORO ELLIPTA AND STIOLTO RESPIMAT FOR COPD​.GSK - ‍ENDPOINT WAS MET, AND UMEC/VI DEMONSTRATED SUPERIORITY TO TIO/OLO, WITH A DIFFERENCE IN TREATMENT EFFECT OF 52ML ON TROUGH FEV1 AT WEEK EIGHT ​.GLAXOSMITHKLINE PLC - ‍MOST FREQUENTLY-REPORTED ADVERSE EVENTS WERE UPPER RESPIRATORY TRACT INFECTIONS, COUGH AND DIARRHOEA​.GLAXOSMITHKLINE PLC - ‍BOTH TREATMENTS DEMONSTRATED A COMPARABLE TOLERABILITY AND SAFETY PROFILE​.GLAXOSMITHKLINE PLC - ‍OVERALL INCIDENCE OF ON-TREATMENT ADVERSE EVENTS OF 25% IN UMEC/VI GROUP AND 31% IN TIO/OLO GROUP​. 

Company Quote

16.14
0.0 +0.00%
12 Nov 2018